Author:
Naseem Nazish,Kushwaha Poonam,Haider Faheem
Publisher
Springer Science and Business Media LLC
Reference126 articles.
1. Abdolahpour S, Mahdieh N, Jamali Z, Akbarzadeh A, Toliyat T, Paknejad M (2017) Development of doxorubicin-loaded nanostructured lipid carriers: preparation, characterization, and in vitro evaluation on MCF-7 cell line. BioNanoScience 7:32–39
2. Abu-Hdaib B, Nsairat H, El-Tanani M, Al-Deeb I, Hasasna N (2024) In vivo evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system. Nanomedicine 25:1–5
3. Alhalmi A, Amin S, Khan Z, Beg S, Al Kamaly O, Saleh A, Kohli K (2022) Nanostructured lipid carrier-based codelivery of raloxifene and naringin: formulation, optimization, in vitro, ex vivo, in vivo assessment, and acute toxicity studies. Pharmaceutics 14(9):1771
4. Al-Ziyadi RKM, Hayati N, Rezaei MR, Es-haghi A (2023) Preparation and characterization of chitosan-coated nanostructured lipid carriers (CS-NLC) containing (6)-gingerol and investigating their toxicity against MCF-7 breast cancer cell line. BioNanoScie, p 1–11
5. Anand U, Dey A, Chandel AK, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK (2022) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10(4):1367–401